Gene Therapy for Alzheimer's Disease Clinical Trial

Plain-language summary

This study examined a gene therapy using human nerve growth factor in patients with Alzheimer's disease. People with a diagnosis of probable Alzheimer's disease in the early stage (generally within three years of onset) could take part. The study was carried out in Phase 1 and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Phase 1

Status

Completed

Sponsor

The Shiley Family Trust

Intervention

Human Nerve Growth Factor

Estimated completion

11/1/2003

Countries

United States

Related genes

Locations

• La Jolla, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

* Neurologist certified diagnosis of probable Alzheimer's disease
* Early stage of Alzheimer's disease (generally within three years of onset)
* Normal speaking ability and normal ability to understand
* Ability to understand the potential risks of participation in this study
* Willing to visit the San Diego area and be available for many visits in the first year
* Willing to discontinue use of drugs Cognex, Aricept, Exelon, or Reminyl for the first 18 months of the trial